All In Biotech

NDA 217639 · Stemline Therap

Orserdu

Elacestrant Hydrochloride · Oral · Estrogen Receptor Antagonist

NovelPriority review

CDER novel approval, Jan 27, 2023: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jan 27, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

39

5 Phase 3, 23 recruiting

FAERS reports

7,181

2,423 serious, 553 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Therapeutic areas: Oncology · Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 27, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterReviewLabel
2 products under this application
  • ORSERDU · ELACESTRANT HYDROCHLORIDE EQ 86MG BASE · TABLET, ORAL · Prescription
  • ORSERDU · ELACESTRANT HYDROCHLORIDE EQ 345MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Elacestrant" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,512
  • fatigue1,130
  • disease progression783
  • vomiting694
  • diarrhoea566
  • death520
  • drug ineffective491
  • constipation408
  • product dose omission issue382
  • decreased appetite377
  • pain374
  • arthralgia342

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20202
20212
20221
20233,022
20243,662
2025330
2026162

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orserdu (Elacestrant HCl)

2024 spending

$259M

Beneficiaries

2,633

11,378 claims

Per beneficiary

$98,308

$703.99 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$127,626,022
2024$258,846,198

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Stemline Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.